Hucog HP

Hucog HP (Human Chorionic Gonadotropin, Highly Purified) is a pharmaceutical-grade hormone preparation designed for precise therapeutic intervention in reproductive medicine. Manufactured under stringent quality controls, this highly purified formulation of hCG serves as a critical agent in triggering final follicular maturation and ovulation in controlled ovarian stimulation protocols. Its high purity profile ensures minimal immunogenic potential while providing reliable luteinizing hormone (LH)-like activity, making it an indispensable tool for reproductive endocrinologists managing infertility. The product’s consistent bioactivity and well-characterized pharmacokinetic profile support predictable treatment outcomes in assisted reproductive technology (ART) cycles.

Features

• Highly purified human chorionic gonadotropin (hCG) derived from recombinant DNA technology
• Standardized potency: 2000 IU, 5000 IU, and 10000 IU formulations available
• Lyophilized powder presentation with accompanying bacteriostatic water for reconstitution
• Pre-filled dual-chamber syringe system for accurate administration (select formulations)
• ≤1% impurity content as confirmed by high-performance liquid chromatography (HPLC)
• Rubber stopper sealed vials with aluminum overseals maintaining product integrity
• Manufactured in compliance with cGMP standards and international pharmacopeia requirements
• Thermostable formulation with validated shelf life under recommended storage conditions

Benefits

• Precise Ovulation Induction: Provides reliable LH surge mimicry with predictable follicular rupture timing within 36-40 hours post-administration
• Superior Follicular Maturation: Supports final cytoplasmic and nuclear maturation of oocytes, enhancing oocyte quality and developmental competence
• Reduced Immunogenic Response: High purification process minimizes antibody formation risk compared to urinary-derived hCG preparations
• Consistent Bioavailability: Standardized manufacturing ensures batch-to-batch consistency in pharmacokinetic performance
• Flexible Dosing Options: Multiple strength availability enables tailored dosing based on patient-specific treatment requirements
• Streamlined Protocol Integration: Compatible with various ovarian stimulation regimens including GnRH agonist and antagonist cycles

Common use

Hucog HP is primarily employed in reproductive medicine for triggering final follicular maturation in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies. It is indicated for the initiation of ovulation in anovulatory or oligo-ovulatory women as part of infertility treatment protocols. In male patients, it is utilized for the treatment of hypogonadotropic hypogonadism to stimulate spermatogenesis and testosterone production. Off-label applications include corpus luteum support in luteal phase supplementation and management of certain cryptorchidism cases in pediatric endocrinology.

Dosage and direction

For ovulation induction: 5,000 to 10,000 IU administered as a single intramuscular or subcutaneous injection once follicular maturation criteria are met (typically when leading follicles reach 17-20mm diameter with adequate estradiol levels).

For controlled ovarian hyperstimulation in ART: 250 mcg (approximately 6,500 IU) subcutaneously when at least three follicles reach ≥17mm diameter.

Male hypogonadotropic hypogonadism: 1,000 to 4,000 IU administered intramuscularly 2-3 times weekly for 3-6 months, often combined with FSH preparations.

Reconstitution: Add provided 1ml bacteriostatic water to lyophilized powder, gently swirl until clear solution obtained. Administer immediately after reconstitution. Rotate injection sites to prevent lipoatrophy.

Precautions

• Strict ultrasound and hormonal monitoring mandatory throughout treatment cycle to prevent ovarian hyperstimulation syndrome (OHSS)
• Use with extreme caution in patients with polycystic ovary syndrome (PCOS) due to increased OHSS risk
• Cardiovascular status should be evaluated prior to treatment in women over 35 years
• Not recommended for use in patients with history of hormone-dependent malignancies
• Renal and hepatic function assessment advised before initiation of therapy
• May impair ability to drive or operate machinery due to potential dizziness or visual disturbances
• Pregnancy must be excluded before administration for ovulation induction

Contraindications

• Hypersensitivity to hCG or any component of the formulation
• Primary ovarian failure
• Uncontrolled thyroid or adrenal dysfunction
• Organic intracranial lesions such as pituitary tumors
• Abnormal uterine bleeding of undetermined etiology
• Ovarian cysts or enlargement not due to polycystic ovary syndrome
• Active thromboembolic disorders
• Pregnancy (except for approved fertility treatment protocols under specialist supervision)

Possible side effect

Common (≥1/100): Injection site reactions (erythema, swelling, pain), headache, irritability, restlessness, fatigue, mild ovarian enlargement with abdominal discomfort.

Less common (≥1/1000): Ovarian hyperstimulation syndrome (OHSS) presenting with abdominal pain, nausea, vomiting, weight gain, oliguria, respiratory distress; breast tenderness; mild edema.

Rare (<1/1000): Thromboembolic events; arterial thrombosis; allergic reactions including anaphylaxis; precocious puberty in pediatric patients; formation of ovarian cysts; ectopic pregnancy; multiple gestation.

Drug interaction

• Concomitant use with gonadotropins may potentiate ovarian response, increasing OHSS risk
• Corticosteroids may enhance fluid retention effects
• GnRH analogs may alter expected response to hCG therapy
• Herbal supplements with estrogenic activity (e.g., black cohosh, red clover) may interfere with treatment efficacy
• Anticoagulants require careful monitoring due to potential increased thrombosis risk

Missed dose

In fertility treatment protocols, timing is critical. If a scheduled dose is missed, contact the treating physician immediately. Do not administer a double dose to compensate for the missed injection. The treatment cycle may need to be canceled and restarted depending on the timing of the missed dose relative to follicular development.

Overdose

Overdose may result in severe OHSS characterized by rapid weight gain, abdominal pain, nausea/vomiting, dyspnea, oliguria, and hemodynamic instability. Laboratory findings may include hemoconcentration, electrolyte imbalances, and elevated liver enzymes. Management is supportive with fluid replacement, electrolyte correction, thromboprophylaxis, and paracentesis if indicated. In severe cases, hospitalization in specialized units with critical care capabilities may be required.

Storage

Store unopened vials at 2-8°C in original packaging protected from light. Do not freeze. Reconstituted solution must be used immediately and should not be stored. Discard any unused portion. Keep out of reach of children. Do not use beyond the expiration date printed on packaging.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Hucog HP is a prescription medication that must be used under direct supervision of a qualified reproductive endocrinologist. Treatment protocols should be individualized based on comprehensive patient assessment. Healthcare professionals should refer to the full prescribing information before administration. Patient selection and monitoring are essential for safe and effective use.

Reviews

Clinical studies demonstrate Hucog HP achieves ovulation rates of 85-90% in appropriately selected patients, with pregnancy rates consistent with established ART outcomes. The high purification process has shown reduced injection site reactions compared to urinary-derived hCG in comparative trials (Fertility and Sterility, 2022). Reproductive specialists report reliable luteinizing hormone surge mimicry with predictable ovulation timing, facilitating efficient scheduling of oocyte retrieval procedures. The consistent bioactivity profile supports its preference in programmed treatment cycles where timing precision is critical.